• S D Costa, G von Minckwitz, G Raab, J U Blohmer, V Dresel, H Eidtmann, J Hilfrich, C Jackisch, E Merkle, G Gademann, and M Kaufmann.
• Zentrum der Frauenheilkunde und Geburtshilfe, J.W. Goethe Universität, Frankfurt am Main, Germany.
• Semin. Oncol. 1999 Jun 1; 26 (3 Suppl 9): 24-31.

AbstractNeoadjuvant chemotherapy has become standard therapy in the management of breast cancer patients with locally advanced disease with inoperable tumors and inflammatory breast cancer. Patients with earlier stage breast cancer and operable tumors may also benefit from treatment with neoadjuvant chemotherapy. Docetaxel (Taxotere; Rhône-Poulenc Rorer, Collegeville, PA) is thought to be one of the most potent agents in the treatment of metastatic breast cancer and is therefore being investigated for its likely benefit in preoperative, neoadjuvant regimens. Several large phase II and randomized phase III trials are evaluating docetaxel as a single agent, in combination, and/or sequentially in the preoperative setting. Preliminary findings demonstrate high complete and partial response rates and a tolerable toxicity profile. These results are consistent with the view that incorporation of docetaxel in neoadjuvant chemotherapy regimens will contribute to improved patient outcome. Ongoing studies will provide important information regarding the most appropriate regimens and schedules of docetaxel to use in the preoperative, neoadjuvant setting.

20 keywords...

hide…